Alterity Therapeutics (ASX:ATH) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ATH 주식 개요

얼터리티 테라퓨틱스 리미티드는 호주에서 알츠하이머병, 헌팅턴병, 파킨슨병 및 기타 신경 질환을 치료하는 치료제를 연구 및 개발하는 회사입니다.

ATH 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	2/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

수익은 연간 32.88% 증가할 것으로 예상됩니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

수익은 향후 3년간 연평균 11.4% 씩 감소할 것으로 예상됩니다.

지난 1년 동안 주주가 크게 희석되었습니다.

최근 3개월간 주가 변동폭 심해

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

+ 2 더 많은 위험

Alterity Therapeutics Limited 경쟁사

Noxopharm

ASX:NOX

AU$29.2m

Biotron

ASX:BIT

AU$17.1m

Patrys

ASX:PAB

AU$12.3m

AdAlta

ASX:1AD

AU$10.3m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Alterity Therapeutics
과거 주가
현재 주가	AU$0.004
52주 최고치	AU$0.008
52주 최저치	AU$0.002
베타	0.68
11개월 변경	14.29%
3개월 변경 사항	0%
1년 변경 사항	-42.86%
33년 변화	-86.21%
5년 변화	-87.88%
IPO 이후 변화	-99.61%

최근 뉴스 및 업데이트

Recent updates

Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Nov 23

주주 수익률

	ATH	AU Biotechs	AU 마켓
7D	33.3%	-2.5%	0.3%
1Y	-42.9%	16.3%	16.0%

수익률 대 산업: ATH 지난 1년 동안 18.5 %를 반환한 Australian Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ATH 지난 1년 동안 11.2 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ATH's price volatile compared to industry and market?
ATH volatility
ATH Average Weekly Movement	30.9%
Biotechs Industry Average Movement	10.5%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.2%
10% least volatile stocks in AU Market	3.6%

안정적인 주가: ATH 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ATH 의 주간 변동성( 32% )은 지난 1년 동안 안정적이었지만 여전히 Australian 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1997	11	David Stamler	alteritytherapeutics.com

얼터리티 테라퓨틱스는 호주에서 알츠하이머병, 헌팅턴병, 파킨슨병 및 기타 신경 질환을 치료하기 위한 치료제를 연구 및 개발하는 회사입니다. 이 회사의 주요 신약 후보물질은 파킨슨병 치료를 위한 임상 1상 시험 중인 ATH434입니다. 또한 다계통위축증 초기 치료제로 임상 2상 중인 ATH434-201, 다계통위축증 진행 치료제로 임상 2상 중인 ATH434-202, 알츠하이머병 치료제로 임상 2a상을 완료한 PBT2를 개발 중입니다.

Alterity Therapeutics Limited 기본 사항 요약

Alterity Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ATH 기본 통계
시가총액	AU$21.28m
수익(TTM)	-AU$19.12m
수익(TTM)	AU$3.75m

5.7x

P/S 비율

-1.1x

P/E 비율

ATH 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ATH 손익 계산서(TTM)
수익	AU$3.75m
수익 비용	AU$214.30k
총 이익	AU$3.54m
기타 비용	AU$22.66m
수익	-AU$19.12m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.0036
총 마진	94.29%
순이익 마진	-509.84%
부채/자본 비율	0%

ATH 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ATH 주식 개요

보상

위험 분석

Alterity Therapeutics Limited 경쟁사

ASX:NOX

AU$29.2m

ASX:BIT

AU$17.1m

ASX:PAB

AU$12.3m

ASX:1AD

AU$10.3m

가격 내역 및 성능

최근 뉴스 및 업데이트

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Recent updates

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 0.406192 million.

Alterity Therapeutics Limited Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of $6 million.

Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review

Alterity Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Alterity Therapeutics Limited Announces CFO Changes

Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease

New minor risk - Shareholder dilution

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 4.8 million.

Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now

Alterity Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy

New major risk - Market cap size

Alterity Therapeutics Limited, Annual General Meeting, Nov 29, 2023

New minor risk - Financial data availability

Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's

Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study

Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder

Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy

Alterity Therapeutics Limited Receives Regulatory Approval for Phase II Trial in France and Austria

Alterity Therapeutics Limited Announces A Study Recently Published in the Journal Neurotherapeutics Demonstrated Its Lead Clinical Asset, Ath34, Was Neuroprotective in A Genetic Model of Parkinson's Disease

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy

Alterity Therapeutics Limited Announces A New Composition of Matter Patent Allowed by the United States Patent and Trademark Office

Insufficient new directors

Alterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting

Alterity Therapeutics Limited, Annual General Meeting, Nov 11, 2022

Alterity Therapeutics Announces Presentation of Wearable Sensor Data from the Biomuse Natural History Study At the International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe

Alterity Therapeutics Limited Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate

Alterity Therapeutics Limited Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

Alterity Therapeutics Limited Launches ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom

Insufficient new directors

Alterity Therapeutics Announces Presentation of bioMUSE Data at the American Academy of Neurology (AAN) Annual Meeting

Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?

Alterity Therapeutics Announces Publication Demonstrating ATH434 Is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson’s Disease

Alterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson’S and Alzheimer’S

Alterity Therapeutics Limited Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial

Alterity Therapeutics Announces Data Was Presented from the Company’s Biomarkers of Progression in Multiple System Atrophy Study

United States Patent and Trademark Office Issues Notice of Allowance for Patent Application of Alterity Therapeutics to Expand its Portfolio of Compounds for Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Announces New Publication Demonstrates ATH434 Is Neuroprotective

Alterity Therapeutics Limited announced that it has received AUD 17.17604 million in funding

Alterity Therapeutics Granted Anew Us Patent Targeting Major Neurodegenerative Diseases Including Alzheimer's and Parkinson's

Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial

We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely

Alterity Therapeutics Limited to Report First Half, 2021 Results on Feb 25, 2021

Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation

Alterity Therapeutics Limited Appoints Dr. David Stamler as CEO

How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?

Alterity Announces Approval of US Patent for Next Generation Compounds to Treat Neurodegenerative Diseases

Alterity Therapeutics Commences Enrolling Multiple System Atrophy Patients in bioMUSE Study